Publications

1. Robbins HA, Ferreiro-Iglesias A, Waterboer T, Brenner N, Nygard M, Bender N, et al. (2022). Absolute risk of oropharyngeal cancer after an HPV16-E6 serology test and potential implications for screening: results from the Human Papillomavirus Cancer Cohort Consortium. J Clin Oncol. 40(31):3613–22. https://doi.org/10.1200/JCO.21.01785 PMID:35700419
2. Alcala K, Mariosa D, Smith-Byrne K, Nasrollahzadeh Nesheli D, Carreras-Torres R, Ardanaz Aicua E, et al. (2022). The relationship between blood pressure and risk of renal cell carcinoma. Int J Epidemiol. 51(4):1317–27. PMID:35312764
3. Feng X, Wu WYY, Onwuka JU, Haider Z, Alcala K, Smith-Byrne K, et al. (2023). Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools. J Natl Cancer Inst. 115(9):1050–9. https://doi.org/10.1093/jnci/djad071 PMID:37260165
4. Zvereva M, Hosen MI, Forey N, Sheikh M, Kannengiesser C, Ba I, et al. (2023). Simplex droplet digital PCR assays for the detection of TERT promoter mutations in urine samples for the non-invasive diagnosis of urothelial cancer. Methods Mol Biol. 2684:213–28. https://doi.org/10.1007/978-1-0716-3291-8_13 PMID:37410237
5. Cortez Cardoso Penha R, Sexton Oates A, Senkin S, Park HA, Atkins J, Holcatova I, et al. (2024). Understanding the biological processes of kidney carcinogenesis: an integrative multi-omics approach. Mol Syst Biol. 20(12):1282–302. https://doi.org/10.1038/s44320-024-00072-3 PMID:39592856
6. Gabriel AAG, Atkins JR, Penha RCC, Smith-Byrne K, Gaborieau V, Voegele C, et al.; ILCCO consortium (2022). Genetic analysis of lung cancer and the germline impact on somatic mutation burden. J Natl Cancer Inst. 114(8):1159–66. https://doi.org/10.1093/jnci/djac087 PMID:35511172
7. Byun J, Han Y, Li Y, Xia J, Long E, Choi J, et al. (2022). Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. Nat Genet. 54(8):1167–77. https://doi.org/10.1038/s41588-022-01115-x PMID:35915169
8. Mathian É, Drouet Y, Sexton-Oates A, Papotti MG, Pelosi G, Vignaud JM, et al. (2024). Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project. ESMO Open. 9(6):103591. https://doi.org/10.1016/j.esmoop.2024.103591 PMID:38878324
9. Dayton TL, Alcala N, Moonen L, den Hartigh L, Geurts V, Mangiante L, et al. (2023). Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites. Cancer Cell. 41(12):2083–2099.e9. https://doi.org/10.1016/j.ccell.2023.11.007 PMID:38086335
10. Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, et al. (2023). Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. Nat Genet. 55(4):607–18. https://doi.org/10.1038/s41588-023-01321-1 PMID:36928603
11. Sheikh M, Mukeriya A, Shangina O, Brennan P, Zaridze D (2021). Postdiagnosis smoking cessation and reduced risk for lung cancer progression and mortality: a prospective cohort study. Ann Intern Med. 174(9):1232–9. https://doi.org/10.7326/M21-0252 PMID:34310171
12. Alcala K, Poustchi H, Viallon V, Islami F, Pourshams A, Sadjadi A, et al. (2023). Incident cancers attributable to using opium and smoking cigarettes in the Golestan Cohort Study. EClinicalMedicine. 64:102229. https://doi.org/10.1016/j.eclinm.2023.102229 PMID:37781157
13. Purdue MP, Dutta D, Machiela MJ, Gorman BR, Winter T, Okuhara D, et al.; BioBank Japan Project; FinnGen (2024). Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions. Nat Genet. 56(5):809–18. https://doi.org/10.1038/s41588-024-01725-7 PMID:38671320
14. Feng X, Zahed H, Onwuka J, Callister MEJ, Johansson M, Etzioni R, et al. (2024). Cancer stage compared with mortality as end points in randomized clinical trials of cancer screening: a systematic review and meta-analysis. JAMA. 331(22):1910–7. https://doi.org/10.1001/jama.2024.5814 PMID:38583868
15. Albanes D, Alcala K, Alcala N, Amos CI, Arslan AA, Bassett JK, et al.; Lung Cancer Cohort Consortium (LC3) (2023). The blood proteome of imminent lung cancer diagnosis. Nat Commun. 14(1):3042. https://doi.org/10.1038/s41467-023-37979-8 PMID:37264016
16. Moody S, Senkin S, Islam SMA, Wang J, Nasrollahzadeh D, Cortez Cardoso Penha R, et al. (2021). Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. Nat Genet. 53(11):1553–63. https://doi.org/10.1038/s41588-021-00928-6 PMID:34663923
17. Senkin S, Moody S, Díaz-Gay M, Abedi-Ardekani B, Cattiaux T, Ferreiro-Iglesias A, et al. (2024). Geographic variation of mutagenic exposures in kidney cancer genomes. Nature. 629(8013):910–8. https://doi.org/10.1038/s41586-024-07368-2 PMID:38693263
18. Brennan P, Davey-Smith G (2022). Identifying novel causes of cancers to enhance cancer prevention: new strategies are needed. J Natl Cancer Inst. 114(3):353–60. https://doi.org/10.1093/jnci/djab204 PMID:34743211
19. Torrens L, Moody S, de Carvalho AC, Kazachkova M, Abedi-Ardekani B, Cheema S, et al. (2025). The complexity of tobacco smoke-induced mutagenesis in head and neck cancer. Nat Genet. (forthcoming)
20. Perdomo S, Abedi-Ardekani B, de Carvalho AC, Ferreiro-Iglesias A, Gaborieau V, Cattiaux T, et al. (2024). The Mutographs biorepository: a unique genomic resource to study cancer around the world. Cell Genom. 4(3):100500. https://doi.org/10.1016/j.xgen.2024.100500 PMID:38325367